# Study to Evaluate the Safety and Effectiveness of Withaferin A as a Treatment to Prevent GvHD in Transplant Patients

> **NCT07724873** · PHASE1,PHASE2 · RECRUITING · sponsor: **Tata Memorial Centre** · enrollment: 54 (estimated)

## Conditions studied

- Hematopoietic Stem Cell Transplant (HSCT)
- GVHD - Graft-Versus-Host Disease
- Hematological Malignancy

## Interventions

- **DRUG:** SWA (standardized root extract of Withania somnifera)

## Key facts

- **NCT ID:** NCT07724873
- **Lead sponsor:** Tata Memorial Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-28
- **Primary completion:** 2029-12-03
- **Final completion:** 2029-12-03
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2026-07-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07724873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07724873, "Study to Evaluate the Safety and Effectiveness of Withaferin A as a Treatment to Prevent GvHD in Transplant Patients". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07724873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*